CLINICAL_TRIALS
trial_result
· 2020-09-02
Clinical Trial Update: Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD [Phase 2]
Summary
A Phase 2 trial evaluating two dose levels of AZD2115 in subjects with moderate to severe COPD has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pearl Therapeutics, Inc. | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Status: COMPLETED